Coya’s ALS pipeline moves on two fronts
Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same immune-cell mechanism. Two pieces of news came out of Coya Therapeutics in a span of a week, and taken together they tell a more complete story than either one does alone. One came fro
<p>Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same immune-cell mechanism. Two pieces of news came out of Coya Therapeutics in a span of a week, and taken together they tell a more complete story than either one does alone. One came fro</p>